BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Both of Genzyme's products are indicated for the treatment ... “Typically, companies are not asked to do that unless FDA or EMEA [the European Medicines Agency] or both have a good level of ...

Raab co-founded Californian company Ardelyx in 2007 after working for years at Genzyme, the developer of ... small molecule therapy under FDA review for the control of serum phosphorus in adult ...

FDA approval wasn’t an easy ride ... in 2006 it was several times the size of the next largest (Genzyme) in terms of revenue, and twice the size in terms of employees. In its Thousand Oaks ...

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin ...

They're finishing up their sort of year of follow up. We'll be submitting that to FDA this year and we would look to have as early as next year, kind of official labeling into that group.

L Becquemont received consulting fees from Sanofi-Aventis, Pfizer and Servier, and lecture fees from Genzyme, GlaxoSmithKline, Bristol-Myers Squibb and Merck Sharp and Dohme. His wife works for ...

Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email.

Bank of Montreal (BMO) announced 10 new CDRs will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed. Ad hoc announcement pursuant to Art. 53 LRFull ...

Common stock issuable under the company’s convertible debt was excluded from the computation of GAAP Weighted-Average Diluted Shares Outstanding when they were anti-dilutive. If converted, for the ...